JULIA SASS: Open Payments
NPI 1003539784 · DAVENPORT, IA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$584 in 22 payments from 10 companies in 2025. Trend: 2023 $926 · 2024 $613 · 2025 $584
Food & beverage: $526Education: $58
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 6 | $122 |
| Axsome Therapeutics, Inc. | 1 | $119 |
| Teva Pharmaceuticals USA, Inc. | 1 | $58 |
| Collegium Pharmaceutical, Inc. | 3 | $57 |
| ABBVIE INC. | 2 | $50 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $45 |
| Lundbeck LLC | 3 | $45 |
| Vanda Pharmaceuticals Inc. | 2 | $40 |
| Alkermes, Inc. | 1 | $26 |
| Neurocrine BioSciences, Inc. | 1 | $22 |
Products named: Auvelity, ABILIFY ASIMTUFII, REXULTI, Jornay PM, VRAYLAR, CAPLYTA, FANAPT, ARISTADA.
Industry payments across IA — which companies pay providers there.
